Implantation of carmustine wafers (Gliadel ® ) for high-grade glioma treatment. A 9-year nationwide retrospective study

ConclusionOver the past 9  years, there is a significant decrease utilisation of CW in France. OS after CW implantation is significantly variable as influenced by many factors such as age, gender or recurrent disease but not by post-operative complications. Compare to previous results, CW may increase the OS and this effect seems more pronounced when adjuvant RT/TMZ is given.

Source: Journal of Neuro-Oncology - January 22, 2020 Category: Cancer & Oncology Source Type: research